Spotify Technology vs Vir Biotechnology Inc. Common Stock — how do they compare? Spotify Technology trades at $519.75 (market cap $107.72B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: Spotify Technology is far larger — about 61.2× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spotify Technology for 111 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SPOT | VIR | |
|---|---|---|
Market Cap | $107.72B | $1.76B |
Volume | 1,447,333 | 2,764,948 |
Sector | Media | Health |
52-Week High | $689.21 | $11.78 |
52-Week Low | $412.75 | $5.12 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $97.72B | $1.32B |
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $527.45, down 0.26% with a bullish technical outlook. The company shows strong fundamental improvement with revenue growing from $11.7B in 2022 to $17.2B in 2025, while turning profitable with net income reaching $2.2B. Recent news highlights Spotify's expansion into health tech through founder Daniel Ek's Neko Health venture and new recommendation algorithm features.
The stock offers growth potential with 62% analyst buy ratings and a $588 consensus target, representing 11% upside. Key risks include recent earnings miss in Q2 2026 and competitive pressures in streaming. Positive cash flow trends and margin expansion support the bullish case, though investors should monitor Q3 2026 results due October 22.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →